BMO Capital analyst Matthew Luchini maintained a Hold rating on Regeneron (NASDAQ: REGN) today and set a price target of $361. The company’s shares closed yesterday at $292.41, close to its 52-week low of $288.16.
According to TipRanks.com, Luchini is a 1-star analyst with an average return of -3.2% and a 36.0% success rate. Luchini covers the Healthcare sector, focusing on stocks such as Spark Therapeutics, Bluebird Bio, and Regulus.
Currently, the analyst consensus on Regeneron is Hold and the average price target is $403, representing a 37.8% upside.
In a report issued on May 1, Guggenheim also downgraded the stock to Hold.
See today’s analyst top recommended stocks >>
The company has a one-year high of $543.55 and a one-year low of $288.16. Currently, Regeneron has an average volume of 929.4K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M.
